002907 Chongqing Pharscin Pharmaceutical
- 13.85
- +1.26+10.01%
Chongqing Pharscin Pharmaceutical News
Chongqing Pharscin Pharmaceutical (SZSE:002907) Investors Are up 16% in the Past Week, but Earnings Have Declined Over the Last Three Years
Chongqing Pharscin Pharmaceutical (002907.SZ) now has four self-developed innovative drugs of cancer class 1.1 under research.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on the investor interaction platform on July 31 that the company now has four independently developed class 1.1 innovative drugs for tumor research projects, with potential indications covering tumor immunity, as well as various solid tumors such as lung cancer, breast cancer, colorectal cancer, pancreatic cancer, etc. Currently, with the progress of project research and development, some projects have been made public or submitted for compound patent applications. The company will also continue to orderly promote the development of research projects under the premise of risk control.
Chongqing Pharscin Pharmaceutical (002907.SZ): The standardized planting base for Atractylodes macrocephala established in Youyang County, Chongqing, covers an area of over one hundred acres.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on its investor interaction platform on July 29th that the company has established a standardized planting base for Atractylodes macrocephala in Youyang County, Chongqing, covering an area of over 100 mu.
Chongqing Pharscin Pharmaceutical (002907.SZ): Currently, the company does not have any traditional Chinese medicine related products for diabetes.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on the investor interactive platform on July 29th that the company currently has no traditional Chinese medicine products related to diabetes.
Chongqing Pharscin Pharmaceutical's Omeprazole Sodium for Injection Completes Registration With Chinese Drug Regulator
Chongqing Pharscin Pharmaceutical (002907.SZ): Intravenous Omeprazole Sodium Completes Domestic Production Drug Filing.
Chongqing Pharscin Pharmaceutical (002907.SZ) announced on July 24th that the company recently learned from the website of the National Medical Products Administration that its product, injection-grade omeprazole sodium, has completed domestic drug registration (application for extension of drug validity), and the registration information has been publicly displayed on the website of the National Medical Products Administration. Injection-grade omeprazole sodium is a classic medication for upper gastrointestinal bleeding and is clinically necessary. It is a product on the national medical insurance list and has been recommended in multiple guidelines. It is the only proton pump inhibitor that has entered the national essential drug list and has a wide range of applications.
Chongqing Pharscin Pharmaceutical (002907.SZ): currently produces vitamin-based health products through commissioned processing.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on its investor interaction platform that the company does not currently have relevant production lines. The vitamin-based health products it currently launches are commissioned for processing, including grape seed vitamin E capsules, B group vitamin tablets, calcium vitamin D vitamin K capsules, vitamin C tablets, collagen vitamin C vitamin E tablets, etc. You can purchase them at Huasen Pharmaceutical flagship store on Tmall, Huasen Health flagship store on Taobao, Huasen Nutrition Dietary Specialty Store on Douyin store, Huasen Pharmacy flagship store on Pinduoduo, and Huasen Medical Flagship Store on jd.com, and follow WeChat public account "Huasen Corporation".
Pharscin Pharmaceutical Gets GMP Certificate for Factory in China's Chongqing Province
Chongqing Pharscin Pharmaceutical (002907.SZ): Montelukast Sodium Granules Passed GMP Compliance Inspection.
On July 17, Golonghui reported that Chongqing Pharscin Pharmaceutical (002907.SZ) was recently issued a "Drug GMP Compliance Inspection Notification" by the Chongqing Drug Administration for the pharmaceutical product Montelukast Sodium Granules. The inspection concluded that it met the requirements of the "Drug Production Quality Management Standards (Revised in 2010)" and passed the pre-marketing inspection for drug GMP compliance. Montelukast Sodium Granules are a first-line medication for controlling childhood asthma and are products entrusted to the company, classified as National Medical Insurance Catalogue Category B. This product is recommended in the "Standardization of Diagnosis and Treatment for Childhood Bronchial Asthma","Guidelines for the Prevention and Treatment of Bronchial Asthma", and "Allergy".
Chongqing Pharscin Pharmaceutical (002907.SZ): Bai Zhu is only used for the company's product production and supply after the harvest period, and is not currently available for external sales.
Chongqing Pharscin Pharmaceutical (002907.SZ) stated on the investors' interactive platform that the company has established a standardized planting base for traditional Chinese medicine Atractylodes macrocephala in Youyang County, Chongqing, and the harvested medicinal materials will only be used for the company's product production and will not be sold to the public for the time being.
Chongqing Pharscin Pharmaceutical (002907.SZ) has launched the 'Yanpin Senhuo' series of health products.
On June 26th, Gelunhui investors asked Chongqing Pharscin Pharmaceutical (002907.SZ) on the investor interaction platform, "Does the company produce vitamins?" The company replied that it has launched the "Yanpin Senhuo" healthy living series of products, which includes a variety of vitamin-based health products such as grape seed vitamin E capsules, B vitamins, calcium vitamin D vitamin K capsules, vitamin C tablets, and collagen vitamin C vitamin E tablets.
Chongqing Pharscin Pharmaceutical (002907.SZ) has received the re-registration approval notice for the chemical raw material active pharmaceutical ingredient magnesium aluminum carbonate.
Chongqing Pharscin Pharmaceutical (002907.SZ) announced on June 25th that the company recently received the Chemistry Active Pharmaceutical Ingredient re-registration approval notice issued by the Chongqing Food and Drug Administration for Aluminum Magnesium Carbonate Chemical Raw Materials. Aluminum Magnesium Carbonate Chewable Tablets are integrated varieties of Active Pharmaceutical Ingredient, and the acquisition of the Chemistry Active Pharmaceutical Ingredient re-registration approval notice ensures the normal production of Aluminum Magnesium Carbonate and effectively guarantees the quality and supply of the active pharmaceutical ingredient. Furthermore, self-production of this chemical raw material can effectively control production costs, making this product more competitive in government procurement. The company will strictly carry out the requirements accordingly.
Chongqing Pharscin Pharmaceuticals Completes Domestic Production Registration for Hepatitis Drug
Chongqing Pharscin Pharmaceutical (002907.SZ) has completed the domestic production pharmaceutical filing for injectable ammonium glycyrrhizinate.
Chongqing Pharscin Pharmaceutical (002907.SZ) announced on June 20 that the company recently learned from the website of the National Medical Products Administration that the company's product, injection-grade ammonium glycyrrhizinate, has completed the domestic production record (new production site, updated production enterprise name or address), and the record information has been made public on the website of the National Medical Products Administration.
Chongqing Pharscin Pharmaceutical (002907.SZ): The self-owned brand Quchang Aolisita capsules are currently in the market introduction period.
On June 18th, 2024, Chongqing Pharscin Pharmaceutical (002907.SZ) held an analyst conference, regarding "How is the sales situation of the company's self-owned brand Quchang Aolisita capsules?" The company replied that the self-owned brand Quchang Aolisita capsules are currently in the market introduction period, and it still takes time to ramp up the volume.
Chongqing Pharscin Pharmaceutical (002907.SZ): Currently, the sales terminals are still mainly public hospitals, and the hospital market accounts for about 70 to 80 percent.
On June 18, 2024, Chongqing Pharscin Pharmaceutical (002907.SZ) held an analyst conference to discuss "What is the proportion of the company's products inside and outside the hospital?" The company replied that its sales terminals are still mainly public hospitals, accounting for about 70-80% of the hospital market. At the same time, the company is collaborating with multiple channels to gradually increase its market share in e-commerce, new media platforms, and "three terminals".
Chongqing Pharscin Pharmaceutical (002907.SZ): now has 4 self-developed oncology Class 1.1 innovative drug research and development projects.
Chongqing Pharscin Pharmaceutical (002907.SZ) said on the investor interaction platform on June 18th that the company now has 4 independently developed class 1.1 innovative drugs for the treatment of tumors. Potential indications covers tumor immunity as well as various solid tumors including lung cancer, breast cancer, colorectal cancer, and pancreatic cancer. Currently, they are in the preclinical stage and the research and development progress is in line with expectations. Some projects have already been publicly disclosed or have submitted compound patent applications.
Pharscin Pharma's Vonoprazan Fumarate Tablets Get Registration Certificate From Chinese Drug Regulator
Chongqing Pharscin Pharmaceutical (002907.SZ): Vor ila acid fumarate tablets (10mg and 20mg) have obtained the pharmaceutical registration certificate.
Chongqing Pharscin Pharmaceutical (002907.SZ) announced on June 17th that the company recently received the "Drug Registration Certificate" (Certificate No.: 2024S01025) and (Certificate No.: 2024S01026) issued by the National Medical Products Administration for the company's product Fumag Venlafaxine Hydrochloride Tablets (10mg and 20mg) (hereinafter referred to as "the drug"). Fumag Venlafaxine Hydrochloride Tablets are a Class B drug in the National Medical Insurance List for version 2023. According to data from Yaozh, the overall market share of Fumag Venlafaxine Hydrochloride Tablets in 2023 was 439 million yuan. The drug is a potassium ion competitive acid.
Chongqing Pharscin Pharmaceutical Co., Ltd.'s (SZSE:002907) Stock Price Dropped 6.5% Last Week; Private Companies Would Not Be Happy
Analysis
Price Target
No Data
